Skip to main content
Erschienen in: Pathology & Oncology Research 1/2019

14.11.2017 | Original Article

RETRACTED ARTICLE: Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway

verfasst von: Xiao-Fei Song, Qi-Hua Wang, Ran Huo

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

This study was conducted in order to elucidate the role microRNA-708 (miR-708) plays between proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) involving melanoma cells by targeting using LEF1 through the Wnt signaling pathway. Male Kunming mice were selected and subsequently divided into normal and model groups to take part in this study. Following cell line selection, the B16 cells with the highest miR-708 expression were selected and assigned into the control, blank, negative control (NC), miR-708 mimic, miR-708 inhibitor, siRNA-LEF1, and miR-708 inhibitor + siRNA-LEF1 groups. A Bioinformatics Web service and dual-luciferase reporter assay were conducted in order to determine the relationship between LEF1 and miR-708. The RT-qPCR method was performed in order to detect the miR-708 expression and mRNA expressions of LEF1, β-catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3, E-cadherin, and western blotting was used in order to detect the protein expressions of these genes. MTT assay, scratch test, Transwell assay, and flow cytometry were all conducted in order to detect the cell proliferation, migration, invasion, and cycle/apoptosis, respectively. LEF1 was verified as the target gene of miR-708. In comparison with the normal group, the model group had reduced expressions of miR-708, Bax, Caspase3, and E-cadherin, while showing elevated expressions of LEF1, β-catenin, Bcl-2, Wnt3a, and N-cadherin. In comparison to the blank and control groups, the miR-708, mimic, and siRNA-LEF1 groups had elevated expressions of Bax, Caspase3, and E-cadherin, while also showing enhanced cell apoptosis. The miR-708, mimic, and siRNA-LEF1 groups also had decreased expressions of LEF1, β-catenin, Bcl-2, Wnt3a, and N-cadherin, and reduced optical density value 48 h and 72 h after transfection. Besides, these two groups showed declined cell migration and invasion, as well as lengthened G0/G1 phase (increased cell number) and shortened S phase (decreased cell number). Our findings demonstrated that an overexpressed miR-708 inhibits the proliferation, invasion, migration, and EMT, but also promotes the apoptosis of melanoma cells by targeting LEF1 through the suppression of the Wnt signaling pathway.

Literatur
  1. Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, Hainaut P, Charles J (2017) Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int 2017:5986129View Article
  2. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, CJ W, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218View Article
  3. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30View Article
  4. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51–65View Article
  5. Wu S, Singh RK (2011) Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med 11:553–563View Article
  6. Melis C, Rogiers A, Bechter O, van den Oord JJ (2017) Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Arch. https://​doi.​org/​10.​1007/​s00428-017-2113-3
  7. Ndoye A Weeraratna AT (2016) Autophagy- an emerging target for melanoma therapy. F1000research 5:1888
  8. Lelli D, Pedone C, Sahebkar A (2017) Curcumin and treatment of melanoma: the potential role of microRNAs. Biomed Pharmacother 88:832–834View Article
  9. Sun V, Zhou WB, Majid S, Kashani-Sabet M, Dar AA (2014) MicroRNA-mediated regulation of melanoma. Br J Dermatol 171:234–241View Article
  10. Luo C, Weber CE, Osen W, Bosserhoff AK, Eichmuller SB (2014) The role of microRNAs in melanoma. Eur J Cell Biol 93:11–22View Article
  11. Leibowitz-Amit R, Sidi Y, Avni D (2012) Aberrations in the micro-RNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma. Pigment Cell Melanoma Res 25:740–757View Article
  12. Li G, Yang F, Xu H, Yue Z, Fang X, Liu J (2015) MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomed Pharmacother 73:154–159View Article
  13. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, Dahiya R (2011) MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 71:6208–6219View Article
  14. Lin KT, Yeh YM, Chuang CM, Yang SY, Chang JW, Sun SP, Wang YS, Chao KC, Wang LH (2015) Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. Nat Commun 6:5917View Article
  15. Murakami T, Saitoh I, Sato M, Inada E, Soda M, Oda M, Domon H, Iwase Y, Sawami T, Matsueda K, Terao Y, Ohshima H, Noguchi H, Hayasaki H (2017) Isolation and characterization of lymphoid enhancer factor-1-positive deciduous dental pulp stem-like cells after transfection with a piggyBac vector containing LEF1 promoter-driven selection markers. Arch Oral Biol 81:110–120View Article
  16. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H (2014) Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 5:5694View Article
  17. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683–695View Article
  18. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT (2013) Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3:1378–1393View Article
  19. Ayuk SM, Abrahamse H, Houreld NN (2016) The role of photobiomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro. J Photochem Photobiol B 161:368–374View Article
  20. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J (2012) Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res 18:3658–3667View Article
  21. Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB, Mittal V (2013) Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 23:63–76View Article
  22. Perez EC, Machado J Jr, Aliperti F, Freymuller E, Mariano M, Lopes JD (2008) B-1 lymphocytes increase metastatic behavior of melanoma cells through the extracellular signal-regulated kinase pathway. Cancer Sci 99:920–928View Article
  23. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P (2005) Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58:1163–1169View Article
  24. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ (2005) Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 65:9851–9860View Article
  25. Guo P, Lan J, Ge J, Nie Q, Mao Q, Qiu Y (2013) miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep 30:870–876View Article
  26. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL (2015) AKT1 activation promotes development of melanoma metastases. Cell Rep 13:898–905View Article
  27. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, Emri G, Koroknai V, Kiss T, Adany R, Balazs M (2012) The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol 33:2189–2199View Article
  28. De Donatis GM, Pape EL, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T (2016) NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. Oncogene 35:2735–2745View Article
  29. Redondo P, Lloret P, Idoate M, Inoges S (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30:541–545View Article
  30. Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J (2013) ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res 73:6068–6079View Article
  31. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, Melamed J, Zhao J, Lee P (2015) LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Mol Cancer Res 13:681–688View Article
  32. Cui XP, Xing Y, Chen JM, Dong SW, Ying DJ, Yew DT (2011) Wnt/beta-catenin is involved in the proliferation of hippocampal neural stem cells induced by hypoxia. Ir J Med Sci 180:387–393View Article
  33. Castiglia D, Bernardini S, Alvino E, Pagani E, De Luca N, Falcinelli S, Pacchiarotti A, Bonmassar E, Zambruno G, D'Atri S (2008) Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosom Cancer 47:614–624View Article
  34. Sun L, Liu T, Zhang S, Guo K, Liu Y (2017) Oct4 induces EMT through LEF1/beta-catenin dependent WNT signaling pathway in hepatocellular carcinoma. Oncol Lett 13:2599–2606View Article
  35. Spangler B, Vardimon L, Bosserhoff AK, Kuphal S (2011) Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma. Pigment Cell Melanoma Res 24:148–164View Article
  36. Qi J, Chen N, Wang J, Siu CH (2005) Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell 16:4386–4397View Article
  37. Chen H, Gao X, Sun Z, Wang Q, Zuo D, Pan L, Li K, Chen J, Chen G, Hu K, Li K, Shah AS, Huang T, Zeeshan Bhatti M, Tong L, Jiao C, Liu J, Chen T, Yao L, Dang Y, Liu T, Li L (2017) REGgamma accelerates melanoma formation by regulating Wnt/beta-catenin signaling pathway. Exp Dermatol 26:1118–1124
Metadaten
Titel
RETRACTED ARTICLE: Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway
verfasst von
Xiao-Fei Song
Qi-Hua Wang
Ran Huo
Publikationsdatum
14.11.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0334-z

Weitere Artikel der Ausgabe 1/2019

Pathology & Oncology Research 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.